A first-of-its-kind study published today in AACC’s Clinical Chemistry journal shows that a novel drug test detects a new class of synthetic cannabinoids called OXIZIDs. This test could enable drug enforcement agencies to identify OXIZID users and could play a critical role in efforts to stop the spread of these drugs.
A first-of-its-kind test could make it easier for newborns to get care for spinal muscular atrophy, a common genetic disease that is life-threatening but treatable if caught in time. Findings on this method and a second innovative test that could improve diagnosis of pediatric urinary tract infections (UTIs) will be discussed today at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo.
Two studies presented today at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo reveal how SARS-CoV-2 antibody levels vary among recipients of COVID-19 vaccines and naturally infected individuals. These findings add to a growing body of knowledge that is essential for guiding public health initiatives, and that might one day enable clinicians to assess individuals’ immunity to SARS-CoV-2.
Scientists have developed a cheap, convenient smartphone test for monitoring patients at risk for dangerous blood clots. Research demonstrating that this test works, along with a second study on using artificial intelligence (AI) to improve testing and treatment for people with kidney stones, will be presented at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo. Both studies could help resolve longstanding challenges in healthcare and laboratory testing.
AACC is pleased to announce the winners of its 2022 Top Corporate Supporter Awards. This year, AACC recognizes 35 different companies and organizations that generously support the association through advertising, sponsorships, and exhibiting. These significant contributions make it possible for AACC to further its mission of better health through laboratory medicine.
At the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo, laboratory medicine experts will present the cutting-edge research and technology that is revolutionizing clinical testing and patient care.
AACC joins more than 100 other medical and patient organizations that have expressed concerns about the Senate HELP committee rushing to pass the VALID Act, a bill that would limit patient access to vital laboratory developed tests and the lifesaving diagnoses these tests enable. Specifically, the medical and patient communities urge Congress to remove the VALID Act from the FDASLA Act, a piece of must-pass legislation that the Senate is on the cusp of ratifying.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce the recipients of the 2022 AACC and AACC Academy Awards. Through this annual awards program, AACC and its academy recognize individuals around the world for outstanding research and service in the field of laboratory medicine, and strive to raise awareness of the vital contribution made by all lab professionals to patient care.
AACC has sent comments to the U.S. Senate Health, Education, Labor & Pensions (HELP) Committee urging the committee not to include the VALID Act in its omnibus Food and Drug Administration (FDA) user fee legislation. VALID would limit the availability of vital laboratory-developed tests, decreasing patient access to life-saving diagnostic tools.
We share the FDA’s goal of alerting the public to the potential misuse of non-invasive prenatal screening (NIPS) tests. This is why we’ve been advocating for the modernization of how laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid Services (CMS).
Laboratory developed tests play a vital role in getting patients accurate diagnoses and effective care, and at no time has their importance been clearer than during the current pandemic. In this briefing, AACC’s leading experts in laboratory medicine will discuss why laboratory developed tests are crucial to fighting the coronavirus, as well as the regulatory barriers that nearly prevented labs from developing and introducing these tests for the virus.
In the face of a chronic shortage of professionals who are qualified to perform clinical laboratory tests—including those for COVID-19—AACC released a position statement today calling on Congress to provide federal funding to expand clinical laboratory training programs. This will help to ensure that labs have the staffing they need to deliver timely, accurate test results, particularly during public health emergencies such as the current coronavirus pandemic.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce a new collaboration with the Centers for Disease Control and Prevention (CDC) and the CDC Foundation that aims to expand lipid testing in resource-limited countries. Improving access to this essential testing could help reduce the high worldwide mortality rate from cardiovascular disease by enabling patients to get treated for this condition earlier.
A novel study in AACC’s Clinical Chemistry journal shows that a new test for SARS-CoV-2 viral proteins known as antigens could determine which COVID-19 patients are most likely to become critically ill. This test could help improve management of COVID-19 by enabling hospitals to ensure that these patients have access to intensive care.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that Senator Roy Blunt (R-Missouri) is the recipient of AACC’s Outstanding Legislator Award for the 116th Congress. This award recognizes Sen. Blunt for his tireless efforts to improve children’s healthcare by advancing the development of pediatric reference intervals.
AACC welcomes a decision from the Department of Health and Human Services that the Food and Drug Administration does not have authority to regulate laboratory developed tests (LDTs) without formal notice-and-comment rulemaking.
A new survey of U.S. clinical laboratories conducted by AACC has found that nearly half of all responding labs still do not have the supplies they need to run COVID-19 tests. AACC presented these findings to the White House Coronavirus Task Force today in a letter that calls on the federal government to take a more active role in alleviating this problem, so that labs can increase their testing capacity in the midst of the virus’s latest surge.
We at AACC would like to thank Assistant Secretary for Health Admiral Brett P. Giroir, MD, for his leadership in establishing the National Testing Implementation Forum to address the persistent challenges that the U.S. is facing with COVID-19 testing and for inviting us to participate in this initiative.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that the impact factor of its journal, Clinical Chemistry, has risen to 7.292 in the 2019 Clarivate Analytics Journal Citation Reports. This impact factor places Clinical Chemistry in the top 4.2% of 12,838 ranked academic journals and speaks to the significant influence of the science it publishes on laboratory medicine and patient care.
In response to the Senate health committee’s white paper on preparing for future pandemics, AACC sent a letter to committee leadership detailing four key steps the government should take to ready the U.S. for the next outbreak. AACC urges the health committee to address these recommendations in future pandemic legislation, as they are crucial to preventing another public health crisis like the one COVID-19 has caused.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that Stephen R. Master, MD, PhD, FAACC, has been elected to serve on the AACC Board of Directors as president-elect starting in August 2020.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that its Board of Directors has appointed Mark J. Golden as CEO effective August 17.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce a new competition that will support cutting-edge research that could significantly improve diagnostic testing and patient care. Winners of the competition will each receive a sample set from AACC’s Universal Sample Bank, which includes blood samples from hundreds of healthy individuals that were collected to aid medical studies.
AACC has issued a new guidance document detailing best practices that hospitals and other healthcare institutions should follow when running a point-of-care testing program. As point-of-care tests emerge for more and more conditions—including COVID-19—the guidance emphasizes that it is essential for laboratory professionals and clinicians to collaborate on point-of-care testing programs to ensure this testing benefits patients.
Laboratory professionals cannot be mute bystanders to inequality. Our legacy is one of service and AACC calls upon our community to be part of the dialogue to promote racial equality.
Now that the latest coronavirus relief package, known as the Heroes Act, has moved forward to the U.S. Senate, AACC has sent a letter to Senate leadership outlining five key recommendations that will improve COVID-19 testing capacity across the U.S. AACC urges the Senate to ensure these recommendations are addressed within the Heroes Act, as they are critical to preventing a second wave of the pandemic.
To ensure the proper use of antibody testing for the novel coronavirus, AACC today issued a public statement detailing the role these tests should play in the management of COVID-19 patients and in the development of public health policy. In particular, the organization emphasizes that healthcare professionals and policymakers should work closely with laboratory experts on antibody testing to ensure that these tests are validated, used appropriately, and interpreted correctly.
A first-of-its-kind study published today in AACC’s Clinical Chemistry journal compared the performance of two COVID-19 antibody tests and found that—even though both tests are FDA authorized—one produced more incorrect results than the other. These findings could help healthcare professionals and researchers to better select antibody tests, which are essential to both treating COVID-19 patients and determining the full extent of the outbreak.
With the first home collection test kit for COVID-19 now authorized by the FDA, AACC is warning that more evidence is needed before the country can rely on home-based kits.
To address some of the confusion surrounding COVID-19 testing, AACC today launched a video series in which leading laboratory experts answer common questions about tests for the pandemic. From persistent supply shortages to the emergence of antibody tests, these videos quickly answer the questions that patients and the general public have been asking.
Now that diagnostic companies can sell COVID-19 antibody tests without FDA authorization, healthcare teams should work closely with clinical laboratory experts to ensure that these tests are thoroughly validated and used appropriately. A new opinion piece in AACC’s Clinical Chemistry journal emphasizes that this is critical to minimizing the risk of inaccurate results from these tests, which could have potentially life-threatening consequences.
AACC commends Congress for responding to the concerns of the clinical laboratory community and including $25 billion in the Paycheck Protection Program and Health Care Enhancement Act that is broadly marked for expanding the nation’s coronavirus testing capacity.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce the recipients of the 2020 AACC and AACC Academy Awards. Through this annual awards program, AACC and its academy recognize individuals worldwide for exceptional research and service in the field of laboratory medicine, and strive to raise awareness that clinical laboratory testing is vital to quality patient care.
With shortages of test components and swabs, labs still face huge obstacles to COVID-19 testing. With new White House guidelines reliant on more testing, AACC is urging the administration to find and coordinate resources so lab experts can do their jobs.
In the wake of FDA’s decision to loosen its emergency use authorization criteria for COVID-19 tests, reports have now been surfacing about unreliable commercial COVID-19 serological tests. While this is a major concern, AACC wants to emphasize that these problematic commercial tests are not the same as laboratory-developed tests–and that we still strongly support FDA’s decision to step back from regulating lab-developed tests for COVID-19.
A first-of-its-kind study published in AACC’s Clinical Chemistry journal has found that low vitamin D levels alone do not cause osteoporotic fractures. This research could resolve the longstanding debate over whether vitamin D supplements prevent these fractures, and indicates that members of the general population should not rely on vitamin D by itself for this purpose.
AACC is pleased to announce that the organization will be able to preserve the complete 2020 AACC Annual Scientific Meeting & Clinical Lab Expo experience for its attendees by moving the meeting to December 13-17, 2020. After carefully monitoring the ongoing global crisis caused by the COVID-19 outbreak, the association’s leadership determined that rescheduling is the best way to safeguard the health of meeting attendees, partners, and staff, which is AACC’s number one priority.
AACC applauds the U.S. Senate for responding to the concerns of the clinical laboratory community and revising the Coronavirus Aid, Relief, and Economic Security (CARES) Act to ensure that it provides insurance coverage for all COVID-19 tests, regardless of whether or not they are performed under an FDA emergency use authorization (EUA).
Breaking research in AACC’s The Journal of Applied Laboratory Medicine shows that the fentanyl in epidurals can pass on to babies during labor. While the infants in this study did not experience adverse effects from this fentanyl transfer, this information is crucial to ensuring that new mothers don’t get falsely accused of fentanyl abuse, which can have dire social repercussions for mother and child.
To facilitate rapid identification of COVID-19 cases, AACC has launched a directory of U.S. clinical laboratories that are, or will be, performing testing for SARS-CoV-2, the virus that causes COVID-19. This directory is designed to help healthcare providers quickly find laboratories that can diagnose patients suspected to have COVID-19.
On March 16, FDA updated its guidance on COVID-19 testing to allow clinical labs to create and perform COVID-19 tests without pursuing FDA emergency use authorization (EUA). AACC commends this decision, which will help speed the expansion of COVID-19 testing at this crucial time. However, the association remains concerned that the Families First Coronavirus Response Act does not provide coverage for COVID-19 tests unless the tests are performed under an EUA. AACC urges Congress to rectify this problem before passing the bill so that all patients will have access to coronavirus testing.
AACC greatly values the work that the U.S. House of Representatives has done to support American families in the midst of the coronavirus outbreak and is supportive of the goals of H.R. 6201, the Families First Coronavirus Response Act. However, we are concerned that the language as currently drafted does not provide coverage for COVID-19 tests performed prior to those tests receiving Emergency Use Authorization (EUA) from the Food & Drug Administration (FDA).
On March 5, U.S. House and Senate lawmakers introduced the VALID Act, which would give the Food and Drug Administration (FDA) new, expansive powers to regulate laboratory developed tests—tests that are already regulated by the Centers for Medicare and Medicaid Services (CMS) and are subject to stringent personnel, quality control, and proficiency testing requirements. This bill promotes duplicative, costly federal regulations for clinical laboratories that will result in decreased patient access to essential medical tests. AACC urges Congress not to act on this bill until its impact on healthcare can be thoroughly evaluated.
AACC thanks the FDA for being responsive to the concerns of the clinical laboratory community and amending the coronavirus guidance to allow CMS-certified labs to develop and implement new tests for coronavirus prior to FDA approval.
In a letter to the Food and Drug Administration (FDA), AACC is urging the agency to allow clinical laboratories to develop coronavirus tests without going through FDA review. Lifting this regulatory requirement is key to ensuring that all patients have access to high-quality coronavirus testing and that healthcare workers have the tools they need to control the spread of this disease in the U.S.
Breaking research in AACC’s Clinical Chemistry journal shows that two new tests accurately diagnose coronavirus infection in about 1 hour. These tests could play a critical role in halting this deadly outbreak by enabling healthcare workers to isolate and treat patients much faster than is currently possible.
AACC today announced that its CEO, Janet B. Kreizman, will retire in the second quarter of 2020. “For the past 7 years, Janet has been a strategic leader for the organization, strengthening the association’s position as the leading voice and hub for laboratory medicine professionals dedicated to advancing quality patient care and improved health outcomes,” said AACC President Dr. Carmen L. Wiley.
Biotin’s upsurge in popularity has led to a parallel rise in incidents of this health supplement interfering with critical medical tests. A new guidance document from AACC urges clinicians and laboratory experts to collaborate to prevent this potentially harmful test interference, and to ensure that patients taking biotin receive high quality care.
Novel research shows that a blood test can differentiate elderly concussion patients with brain tissue damage from those without it. This finding, published in the special brain health collection of AACC’s The Journal of Applied Laboratory Medicine, could help ensure that elderly patients with severe concussions receive crucial treatment for their injuries.
In a special brain health collection, AACC’s The Journal of Applied Laboratory Medicine highlights the innovative clinical tests that laboratory medicine experts are developing to improve care for concussions.